Clinical research progress of rasagiline in the treatment of early Parkinson's disease

Rasagiline (Rasagiline) is a selective monoamine oxidaseB (MAO-B) inhibitor that is widely used to treat early Parkinson's disease (PD). It inhibits the metabolism of dopamine in the brain and prolongs the action time of dopamine, thereby improving the patient's motor function. In recent years, clinical research on rasagiline in the treatment of early Parkinson's disease has continued to deepen, and a wealth of efficacy and safety data have been accumulated.

Multiple clinical trials have shown that rasagiline monotherapy can effectively delay the progression of symptoms and improve exercise ability in patients with early-stage Parkinson's disease. Some studies have shown that rasagiline not only significantly improves patients' Unified Parkinson's Disease Rating Scale (UPDRS) scores, but also has certain neuroprotective potential and may have a positive impact on the long-term development of the disease. Compared with traditional dopamine replacement therapy, rasagiline has a rapid onset of action and is well tolerated.

In addition, research on rasagiline combined with other Parkinson's disease drugs has also achieved positive results. For example, when used in combination with levodopa, it can prolong the curative effect of levodopa, reduce the occurrence of the "on-off" phenomenon, and improve the patient's quality of life. Multi-center randomized controlled trials further confirmed the safety and effectiveness of its combination therapy, providing strong support for clinical individualized treatment plans.

Overall, rasagiline has broad prospects for use in the treatment of early Parkinson's disease. As more long-term follow-up and real-world study data accumulate, its role in disease management will become clearer. Future research will also focus on its potential neuroprotective mechanisms and its combined application with new treatment strategies, in order to provide patients with more comprehensive and personalized treatment options.

Reference materials:https://www.azilect.com/

xa0